Pegcetacoplan Alternatives Compared
| Pegcetacoplan | Ultomiris (ravulizumab) | Empaveli (pegcetacoplan) |
|
|---|
| Pegcetacoplan | Ultomiris (ravulizumab) | Empaveli (pegcetacoplan) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Paroxysmal Nocturnal Hemoglobinuria. Pegcetacoplan may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Myasthenia Gravis, Hemolytic Uremic Syndrome, Neuromyelitis Optica Spectrum Disorder, Paroxysmal Nocturnal Hemoglobinuria. Ultomiris may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Paroxysmal Nocturnal Hemoglobinuria. Empaveli may also be used for purposes not listed in this medication guide. |
Related suggestions Paroxysmal Nocturnal Hemoglobinuria
|
|||||||||||||||
| More about Pegcetacoplan | More about Ultomiris (ravulizumab) | More about Empaveli (pegcetacoplan) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Ultomiris has an average rating of 9.6 out of 10 from a total of 7 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Pegcetacoplan side effects |
View all Ultomiris side effects |
View all Empaveli side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Ultomiris prices |
View all Empaveli prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Empaveli |
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
192 hours |
1192.8 hours |
192 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 80 drugs are known to interact with Pegcetacoplan:
|
A total of 87 drugs are known to interact with Ultomiris:
|
A total of 80 drugs are known to interact with Empaveli:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
May 14, 2021 |
December 21, 2018 |
N/A |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Fabhalta
Fabhalta is used to treat paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A ...
Soliris
Soliris infusion is used to treat paroxysmal nocturnal hemoglobinuria (PNH) or neuromyelitis optica ...
Ultomiris
Ultomiris (ravulizumab-cwvz) is used for the treatment of myasthenia gravis, paroxysmal nocturnal ...
Empaveli
Empaveli (pegcetacoplan) is an immunosuppressant that is given by subcutaneous (under the skin) ...
Voydeya
Voydeya (danicopan) is an oral complement factor D inhibitor that may be used to treat ...
Bkemv
Bkemv (eculizumab-aeeb) is an interchangeable biosimilar to Soliris which may be used to treat ...
Epysqli
Epysqli (eculizumab-aagh), a biosimilar to Soliris, targets the complement system to treat ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.